Skip to content
All resources

ERR and AMPK research

SLU-PP-332 vs SLU-PP-915: How the Two ERR Agonists Differ

JH

By

· 10 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 8 sections
  1. What are estrogen-related receptors?
  2. SLU-PP-332 vs SLU-PP-915 at a glance
  3. SLU-PP-332: the original exercise-mimetic paper
  4. SLU-PP-915: a different chemical series
  5. Did either compound work in heart failure?
  6. What the mouse data cannot tell you
  7. Small molecules sold as "peptides"
  8. Frequently asked questions

SLU-PP-332 and SLU-PP-915 are synthetic small molecules, not peptides. Both come from the same Saint Louis University group, and both switch on all three estrogen-related receptors (ERRα, ERRβ and ERRγ). They are structurally distinct. SLU-PP-332 came first and is most potent at ERRα. SLU-PP-915 belongs to a later thiophene–boronic acid series built for better metabolic stability and bioavailability. Each has been examined only in cells and mice, mainly for exercise capacity, obesity and heart failure. Neither has been tested in people or approved anywhere.

Two similar small-molecule ball-and-stick models side by side, one teal and one navy
Illustration, not the exact structures: two closely related small molecules.

Despite the name, ERRs are not estrogen receptors and do not respond to estrogen. They are orphan nuclear receptors, meaning no natural hormone that activates them has been identified. They were named for their sequence resemblance to the estrogen receptor. Like other nuclear receptors, they sit on DNA and control which genes are transcribed. Their targets include genes for mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation and the Krebs cycle. Genetic studies tie them to skeletal muscle's adaptation to endurance exercise.

That is why this pair gets called "exercise mimetics". If training drives an oxidative gene programme partly through ERRs, a molecule that activates ERRs directly might drive part of that programme without the training. Whether that works in a whole organism, and at what cost, is what the mouse papers try to answer. The idea overlaps with AMPK activation, a different route to the same set of oxidative genes, discussed in our article on ATX-304 (O304), and with the MOTS-c literature.

The three subtypes are not interchangeable. In the papers below, ERRα is the subtype tied to the acute exercise response in skeletal muscle, while ERRα and ERRγ are both described as essential regulators of cardiac metabolism. ERRβ gets the least attention. A "pan" agonist hits all three, but potency at each subtype still differs, and that difference shows up in the results.

SLU-PP-332 vs SLU-PP-915 at a glance

SLU-PP-332SLU-PP-915
Chemical classNon-peptide small moleculeNon-peptide small molecule; 2,5-disubstituted thiophene carrying a boronic acid
First described2023, ACS Chemical Biology2023, European Journal of Medicinal Chemistry
Receptor profilePan-ERR, highest potency at ERRαPan-ERR; series designed for ERRγ, with roughly equivalent activity at ERRα and ERRβ
Design problem it addressedFew synthetic ERRα agonists usable in living animalsMetabolic stability, and the bioavailability SLU-PP-332 lacked
Exercise capacity (mice)Increased endurance and oxidative type IIa fibres; effect depended on ERRαSimilar gains in running distance and duration to SLU-PP-332 at comparable exposure
Obesity and metabolic syndrome (mice)Diet-induced obese and ob/ob mice: higher energy expenditure, lower fat mass, better insulin sensitivityNot reported in a dedicated paper we found
Heart failure (mice)Pressure-overload model: higher ejection fraction, less fibrosis, better survivalSame model, same paper, similar results
Other modelsAged mouse kidney; cultured human muscle cellsGene-expression work in vitro and in vivo
Human studiesNoneNone
Regulatory statusNot approved anywhereNot approved anywhere

SLU-PP-332: the original exercise-mimetic paper

Billon and colleagues introduced SLU-PP-332 in 2023 as a pan-ERR agonist with its highest potency at ERRα. That was notable in itself: the abstract notes that ERRβ/γ agonists had been made before, but ERRα agonism had proved hard to achieve. In a skeletal muscle cell line, the compound increased mitochondrial function and cellular respiration. In mice it increased the proportion of oxidative type IIa muscle fibres and increased exercise endurance. The authors also showed that it triggered an ERRα-specific acute aerobic exercise gene programme, and that ERRα activation was required for the endurance effect (PMID 36988910). That dependence experiment is the strongest part of the paper. It links the outcome to the intended target rather than to some off-target action of the molecule.

The same group then took SLU-PP-332 into diet-induced obese and leptin-deficient (ob/ob) mice. They reported higher whole-body energy expenditure and fatty-acid oxidation, less fat-mass accumulation and better insulin sensitivity (PMID 37739806). A separate collaboration treated 21-month-old mice for eight weeks. It reported reversal of age-related albuminuria, podocyte loss, mitochondrial dysfunction and inflammatory cytokines in the kidney, which the authors compared to the effect of caloric restriction (PMID 37717940).

The only "human" SLU-PP-332 work we found is in a dish. Bonanni and colleagues took muscle biopsies from women having hip replacement surgery and grew myoblasts from the inactive group. Treating those cells with SLU-PP-332 shifted markers of oxidative stress, mitochondrial signalling and differentiation (PMID 40692696). That is human tissue, not a human study. No person was given the compound.

SLU-PP-915: a different chemical series

SLU-PP-915 is not a modified SLU-PP-332. Hampton and colleagues started from an older acyl hydrazide ERRγ agonist template (GSK-4716) and used structure-based design to build a new series of 2,5-disubstituted thiophenes. Swapping a phenol or aniline group for a boronic acid preserved activity and improved metabolic stability in liver microsome assays. The series turned out to be roughly equally active at ERRα and ERRβ as well, so it is a pan-agonist too. SLU-PP-915 raised the expression of classic ERR target genes in cells and in mice, including PGC-1α, LDHA, DDIT4 and PDK4 (PMID 37421886).

Its main advantage over SLU-PP-332 is pharmacokinetic. The group's later exercise paper states that SLU-PP-332 is poorly bioavailable, which limits it as a tool for longer studies. SLU-PP-915 was reported to be bioavailable in mice and to produce gains in running distance and duration similar to SLU-PP-332's once systemic exposure was taken into account. Both compounds induced Ddit4, a gene switched on by acute aerobic exercise, at levels matching or exceeding those from treadmill running depending on the muscle. In trained mice, SLU-PP-915 added to the training effect on Ddit4 and mitochondrial gene expression (PMID 41421047). In other words, the newer molecule was built as a better tool for long-term mouse studies. It was not shown to do anything SLU-PP-332 cannot.

Did either compound work in heart failure?

In mice, both did, in the same experiment. Xu, Billon and colleagues tested SLU-PP-332 and SLU-PP-915 side by side in a pressure-overload model of heart failure. Both improved ejection fraction, reduced fibrosis and improved survival without changing the degree of cardiac hypertrophy. RNA sequencing and metabolomics showed fatty-acid and oxidative-phosphorylation pathways being switched back on (PMID 37961903). Genetic dependency experiments identified ERRγ, not ERRα, as the main mediator in heart muscle cells.

This is the most useful detail for anyone comparing the two compounds. The same pan-agonist profile works through different subtypes in different tissues: ERRα in skeletal muscle endurance, ERRγ in the stressed heart. Comparing the molecules by a single potency number misses that.

What the mouse data cannot tell you

Every in vivo result above comes from mice. Every one comes from the Saint Louis University group or its collaborators, and several authors disclose patents or holdings in companies developing ERR modulators. None of that is unusual for a young compound series. It does mean the findings have not yet been independently replicated, which matters most in a field where effect sizes tend to shrink as samples grow (see how to read a peptide study).

The gaps are specific:

  • No human pharmacokinetics or safety data. ERRs regulate transcription in many tissues, including the heart, kidney and muscle studied in these papers. Long-term activation in a healthy organism has not been characterised.
  • "Exercise mimetic" describes a gene programme, not a person. A mouse running further on a treadmill after an ERR agonist is a fact about that model. It is not evidence that the compound substitutes for training in humans.
  • Short studies. The disease-model papers run for weeks, not the lifespan-scale periods over which off-target transcriptional effects would show up.

Anti-doping scientists are already paying attention. An anti-doping research group characterised how human liver fractions metabolise both molecules: nine metabolites for SLU-PP-332, including conjugates, and seven for SLU-PP-915, all phase I. The stated purpose is detecting misuse as performance-enhancing substances (PMID 41588687). The group has also published a structure–activity study of the SLU-PP-332 scaffold, which suggests further analogues are coming (PMID 41850449).

Small molecules sold as "peptides"

Both compounds often appear in peptide catalogues, which causes the same category error discussed in our article on 5-amino-1MQ. They are not amino-acid chains. They are synthesised by organic chemistry rather than peptide synthesis, and their identity and impurity profile need small-molecule methods to confirm. Neither is carried in this catalogue. Neither has a drug identification number or any approval in Canada or elsewhere, and no human trial of either is registered on ClinicalTrials.gov. In Canada, a compound sold for research use is not an authorised drug; the framework is set out in peptides and Canadian law. Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

Is SLU-PP-915 a newer version of SLU-PP-332? Not chemically. It came out of a separate thiophene–boronic acid series designed from an older ERRγ agonist template. It is newer and was developed partly to fix SLU-PP-332's poor bioavailability, but the two are structurally distinct molecules that happen to share a pan-ERR activity profile and a laboratory.

Which one is more selective for ERRα? SLU-PP-332 was reported to have its highest potency at ERRα, and its mouse endurance effect depended on ERRα. SLU-PP-915's series was designed for ERRγ and showed roughly equivalent activity at ERRα and ERRβ. In heart tissue, ERRγ turned out to drive the response to both compounds, so subtype selectivity depends on the tissue.

Are SLU-PP-332 or SLU-PP-915 peptides? No. Both are synthetic small molecules made by organic chemistry, not chains of amino acids. They are sometimes listed alongside peptides because they are sold through the same research-chemical channels, but their chemistry, analysis and stability have nothing in common with peptides.

Has either compound been tested in humans? No. We found no published human study and no registered human trial of either compound. The closest is a laboratory experiment in which SLU-PP-332 was applied to muscle cells grown from human biopsies. That shows a response in cultured human cells, not anything about giving the compound to a person.

Do they bind the estrogen receptor? They are designed to act on the estrogen-related receptors, a separate family of orphan nuclear receptors named for their sequence resemblance to the estrogen receptor. ERRs do not respond to estrogen. The papers characterise activity at ERRα, β and γ; they are not described as estrogen-receptor agonists.

Selected Research References

  1. Billon C, Sitaula S, Banerjee S, et al. Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity. ACS Chem Biol. 2023;18(4):756-771. pubmed.ncbi.nlm.nih.gov/36988910
  2. Hampton CS, Sitaula S, Billon C, et al. Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915. Eur J Med Chem. 2023;258:115582. pubmed.ncbi.nlm.nih.gov/37421886
  3. Billon C, Schoepke E, Avdagic A, et al. A synthetic ERR agonist alleviates metabolic syndrome. J Pharmacol Exp Ther. 2024;388(2):232-240. pubmed.ncbi.nlm.nih.gov/37739806
  4. Xu W, Billon C, Li H, et al. Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function. Circulation. 2024;149(3):227-250. pubmed.ncbi.nlm.nih.gov/37961903
  5. Wang XX, Myakala K, Libby AE, et al. Estrogen-related receptor agonism reverses mitochondrial dysfunction and inflammation in the aging kidney. Am J Pathol. 2023;193(12):1969-1987. pubmed.ncbi.nlm.nih.gov/37717940
  6. Bonanni R, Falvino A, Matticari A, et al. Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study. Front Physiol. 2025;16:1616693. pubmed.ncbi.nlm.nih.gov/40692696
  7. Billon C, Appourchaux K, Côté I, Burris TP. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. J Pharmacol Exp Ther. 2026;393(1):103787. pubmed.ncbi.nlm.nih.gov/41421047
  8. Möller T, Krug O, Thevis M. In vitro metabolism and analytical characterization of SLU-PP-332 and SLU-PP-915: novel pan-ERR agonists with doping potential. Rapid Commun Mass Spectrom. 2026;40(8):e70039. pubmed.ncbi.nlm.nih.gov/41588687
  9. Okda HE, Zhao P, Hayes M, et al. Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling. Int J Biol Macromol. 2026;355:151450. pubmed.ncbi.nlm.nih.gov/41850449

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.